Down-modulation of MHC-I in a CD4+ T cell line, CEM-E5, after HIV-1 infection

J A Scheppler1, J K Nicholson, D C Swan

  • 1Immunology Branch, United States Department of Health and Human Services, Atlanta, GA 30333.

Insights

Human immunodeficiency virus type 1 (HIV-1) infection decreases the expression of MHC class I (MHC-I) molecules on infected cells. This down-regulation impairs the cells

Area of Science:

  • Immunology
  • Virology
  • Molecular Biology

Background:

  • Human immunodeficiency virus type 1 (HIV-1) infects CD4+ cells, leading to significant immune defects.
  • The expression of Major Histocompatibility Complex class I (MHC-I) molecules is crucial for immune surveillance and T cell recognition.

Purpose of the Study:

  • To investigate the impact of HIV-1 infection on the expression of MHC-I molecules on CD4+ cells.
  • To determine if altered MHC-I expression affects the susceptibility of infected cells to immune responses.

Main Methods:

  • In vitro infection of CD4+ peripheral blood lymphocytes (PBL) and CD4+ cell lines (CEM-E5, HT, U937) with HIV-1.
  • Analysis of cell surface MHC-I expression using flow cytometry and radioimmunoprecipitation.
  • Assessment of MHC-I mRNA levels.
  • Evaluation of target cell susceptibility to cytotoxic T lymphocyte (CTL) lysis.

Main Results:

  • HIV-1 infection transiently down-regulates MHC-I expression on CD4+ PBL within 18-24 hours.
  • In CEM-E5 cells, MHC-I down-regulation correlates with viral production, decreasing by up to 40%.
  • The decrease in surface MHC-I is due to reduced total protein and lower MHC-I mRNA levels, not selection of low-expressing cells.
  • HIV-1 infected CEM-E5 cells exhibit reduced susceptibility to CTL-mediated lysis.

Conclusions:

  • HIV-1 infection actively modulates MHC-I expression, contributing to immune evasion.
  • Down-regulation of MHC-I may represent a mechanism by which HIV-1 infected cells avoid immune destruction.
  • Understanding this interaction is vital for developing therapeutic strategies against HIV-1.